Press Releases
Driven. For Client Success.
For Jinyong Kim, Samsung Biologics’ new Plant 4 is the project of a lifetime. As a leader in the Global Sales Center’s alliance management group, he ensures that we’re delivering industry-leading contract manufacturing and development services to support our clients’ current needs, but also their long-term supply chain strategy as well. With the demand in biopharmaceutical services consistently rising, Jinyong is driven to help clients achieve our shared goal of providing high-quality medicines to patients faster than anyone. That’s where Plant 4 comes in.
As a one-stop shop allowing significant savings in cost and time for our clients, Plant 4 is expected to be the world’s largest biomanufacturing facility of its kind, boasting 256,000 liters of total manufacturing capacity, and will provide process flexibility for clients to scale up or down during the full lifecycle of their products. Upon its completion, Samsung Biologics is estimated to be accountable for approximately one-fourth of the total global mAb CDMO manufacturing capacity, offering a combined sum of 620,000 liters from a single site.
Hear Jinyong discuss how by building our innovative, multi-scale Plant 4, we’ll be meeting the growing market demand and rapidly evolving expectations of our clients as well as what makes Samsung Biologics culture so special.
What are your job responsibilities at Samsung Biologics?
I oversee business relationships with 80+ global clients. Our group’s goal is, largely speaking, two-fold: existing client relationship management and business expansion. All our projects need constant care…so we provide extra hands to make sure the projects are there to meet our clients’ needs, and through that entire process, we want to earn their trust.
Plant 4 is Samsung Biologics’ most ambitious project to date. Can you briefly explain why that is?
It’s truly a mega-project. We’re investing over $1.5 billion into it, and it will be the single biggest plant in the world. With a total capacity of 256,000 liters, it comes with 12 15KL bioreactors, six 10KL, and eight 2KL. Putting all the pieces together means we’ll be providing a wide variety of flexibility in terms of scale to our clients. It really symbolizes the rapid growth of Samsung Biologics from where we were in the past 10 years, where we are now, and where we’re heading in the future.
Can you give insight behind our decision to expand to this large of scale?
The biologics drug industry is evolving at an unprecedented pace. Biologics bring much more value to patients compared to traditional medicines from an efficacy standpoint, which is why not only has the demand gone up, but also the manufacturing and accessibility challenges that come along with it. I believe Samsung Biologics is uniquely well positioned to solve, and close the gap from that perspective. Our state-of-the art EPCV capabilities, combined with a quality-driven operational excellence, will really help our pharma clients bring the drugs to the market in an effective and efficient way.
What are some of the plant’s unique features and how will we leverage it for new and existing projects once it’s up and running?
First and foremost, flexibility is integral. As I mentioned before, Plant 4 comes with a variety of scales – 15K, 10K, and 2K. Market demand is really unpredictable in nature so this will help our clients to be able to adjust in terms of the market trends. The other feature I want to highlight is quality. Plant 4 will operate under the same philosophy and quality protocol [that we use in our existing plants]. It will obviously help us to maintain the highest industry standard for the quality of the product that we’re making across all the plants. Finally, in order to keep up with the market trends, we’ve been preparing [for Plant 4] to have a high degree of digitalization and sustainability. With the combination of everything, we are confident that Plant 4 will satisfy not only our existing clients but future potential clients as well.
Where are we currently in the construction process and when do we expect it to be operational?
Plant 4 construction is progressing on schedule, and many of our clients are already asking for operations to commence as soon as possible. In order to meet this demand, we decided to take a phased approach where we get part of the plant up and running earlier than the other portion; so a 10KL bioreactor suite will be ready by Q4 2022, while the other portion including a 15KL bioreactor facility will be ready around Q3 2023.
What makes Samsung Biologics’ culture unique?
The first word that came to my mind was agile. The market and industry itself are changing faster than ever before. It takes a lot of innovation and constant changes, which we’re doing. We’re bringing the latest technology to our facilities, and we spend day and night trying to come up with better solutions to those market evolutions. Having this agile mindset across the company really helps to bring us closer to clients.
The other aspect that I like about Samsung Biologics’ culture is its global thinking. In the past I’ve worked for Korean companies as well as US companies, and working here it feels as if I’m working for more of a Western company in terms of our daily operation and communication. As a leader in the industry, I think being able to serve our global clients through close communication is important. My colleagues are well versed in Korean and English communications, which helps us to better serve our clients and address their needs [on the local and global level].
When you hear the phrase "Driven. For Life.", what comes to mind?
I love the phrase ‘Driven. For Life.’ It helps me not to lose focus on what I’m doing every day…and why we do this business. What we’re making is actually saving people’s lives, saving our families’ lives. It gives me such a reward that no other job could have brought. I think all Samsung Biologics colleagues should be really proud of what we’re doing.
Related Contents
Microsite Samsung Biologics Plant 4
Press Release Samsung Biologics breaks ground on Super Plant
YouTube Samsung Biologics Plant 4: Operational Excellence
Life @ Samsung Biologics Driven. For Client Satisfaction.
For Jinyong Kim, Samsung Biologics’ new Plant 4 is the project of a lifetime. As a leader in the Global Sales Center’s alliance management group, he ensures that we’re delivering industry-leading contract manufacturing and development services to support our clients’ current needs, but also their long-term supply chain strategy as well. With the demand in biopharmaceutical services consistently rising, Jinyong is driven to help clients achieve our shared goal of providing high-quality medicines to patients faster than anyone. That’s where Plant 4 comes in.
As a one-stop shop allowing significant savings in cost and time for our clients, Plant 4 is expected to be the world’s largest biomanufacturing facility of its kind, boasting 256,000 liters of total manufacturing capacity, and will provide process flexibility for clients to scale up or down during the full lifecycle of their products. Upon its completion, Samsung Biologics is estimated to be accountable for approximately one-fourth of the total global mAb CDMO manufacturing capacity, offering a combined sum of 620,000 liters from a single site.
Hear Jinyong discuss how by building our innovative, multi-scale Plant 4, we’ll be meeting the growing market demand and rapidly evolving expectations of our clients as well as what makes Samsung Biologics culture so special.
What are your job responsibilities at Samsung Biologics?
I oversee business relationships with 80+ global clients. Our group’s goal is, largely speaking, two-fold: existing client relationship management and business expansion. All our projects need constant care…so we provide extra hands to make sure the projects are there to meet our clients’ needs, and through that entire process, we want to earn their trust.
Plant 4 is Samsung Biologics’ most ambitious project to date. Can you briefly explain why that is?
It’s truly a mega-project. We’re investing over $1.5 billion into it, and it will be the single biggest plant in the world. With a total capacity of 256,000 liters, it comes with 12 15KL bioreactors, six 10KL, and eight 2KL. Putting all the pieces together means we’ll be providing a wide variety of flexibility in terms of scale to our clients. It really symbolizes the rapid growth of Samsung Biologics from where we were in the past 10 years, where we are now, and where we’re heading in the future.
Can you give insight behind our decision to expand to this large of scale?
The biologics drug industry is evolving at an unprecedented pace. Biologics bring much more value to patients compared to traditional medicines from an efficacy standpoint, which is why not only has the demand gone up, but also the manufacturing and accessibility challenges that come along with it. I believe Samsung Biologics is uniquely well positioned to solve, and close the gap from that perspective. Our state-of-the art EPCV capabilities, combined with a quality-driven operational excellence, will really help our pharma clients bring the drugs to the market in an effective and efficient way.
What are some of the plant’s unique features and how will we leverage it for new and existing projects once it’s up and running?
First and foremost, flexibility is integral. As I mentioned before, Plant 4 comes with a variety of scales – 15K, 10K, and 2K. Market demand is really unpredictable in nature so this will help our clients to be able to adjust in terms of the market trends. The other feature I want to highlight is quality. Plant 4 will operate under the same philosophy and quality protocol [that we use in our existing plants]. It will obviously help us to maintain the highest industry standard for the quality of the product that we’re making across all the plants. Finally, in order to keep up with the market trends, we’ve been preparing [for Plant 4] to have a high degree of digitalization and sustainability. With the combination of everything, we are confident that Plant 4 will satisfy not only our existing clients but future potential clients as well.
Where are we currently in the construction process and when do we expect it to be operational?
Plant 4 construction is progressing on schedule, and many of our clients are already asking for operations to commence as soon as possible. In order to meet this demand, we decided to take a phased approach where we get part of the plant up and running earlier than the other portion; so a 10KL bioreactor suite will be ready by Q4 2022, while the other portion including a 15KL bioreactor facility will be ready around Q3 2023.
What makes Samsung Biologics’ culture unique?
The first word that came to my mind was agile. The market and industry itself are changing faster than ever before. It takes a lot of innovation and constant changes, which we’re doing. We’re bringing the latest technology to our facilities, and we spend day and night trying to come up with better solutions to those market evolutions. Having this agile mindset across the company really helps to bring us closer to clients.
The other aspect that I like about Samsung Biologics’ culture is its global thinking. In the past I’ve worked for Korean companies as well as US companies, and working here it feels as if I’m working for more of a Western company in terms of our daily operation and communication. As a leader in the industry, I think being able to serve our global clients through close communication is important. My colleagues are well versed in Korean and English communications, which helps us to better serve our clients and address their needs [on the local and global level].
When you hear the phrase "Driven. For Life.", what comes to mind?
I love the phrase ‘Driven. For Life.’ It helps me not to lose focus on what I’m doing every day…and why we do this business. What we’re making is actually saving people’s lives, saving our families’ lives. It gives me such a reward that no other job could have brought. I think all Samsung Biologics colleagues should be really proud of what we’re doing.
Related Contents
Microsite Samsung Biologics Plant 4
Press Release Samsung Biologics breaks ground on Super Plant
YouTube Samsung Biologics Plant 4: Operational Excellence